Bezuclastinib

Name: Bezuclastinib in Gastrointestinal stromal tumor: mTOR inhibitor and tyrosine kinase inhibitor combinations
Published: 2026-09-14T15:39:06-04:00

Gastrointestinal stromal tumor

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted April 2026
Launch: Anticipated in the second half of 2026
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

mTOR inhibitor and tyrosine kinase inhibitor combinations

1 evidence topic · 1 source

Combination options in selected circumstances

“TKIs to be considered for use in combination with everolimus include imatinib, sunitinib, or regorafenib.” (opens the source at this quote in a new tab)